- Active not recruitingPHASE2, PHASE3
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
This study is looking at a new medicine, EYE103, for people with a common eye condition called diabetic macular oedema (DME). It compares EYE103 with a standard treatment, ranibizumab, to see if it's safe and helps improve vision.
For: Diabetic Macular Edema (DME)United States · Argentina · Australia - AuthorisedPhase III and phase IV (Integrated)
Multicentre, randomised, double-blind, parallel-group, Phase III study to evaluate the genetic polymorphisms influence in the response to Ranibizumab and Bevacizumab treatment in patients with Age-Associated Macular Degeneration
This study looks at how well two common eye medicines, ranibizumab and bevacizumab, work for people with Age-Related Macular Degeneration (AMD). Researchers are also checking if a person's genes affect how well these treatments work. The main goal is to see changes in eyesight after one year.
For: Age-Associated Macular DegenerationSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (Neovascular) Age-Related Macular Degeneration
This study is testing a new version of an eye medicine, ranibizumab (like Lucentis), for wet age-related macular degeneration. Researchers want to see if the new version works as well and is as safe as the original to help people see better.
For: wet macula degenerationSlovakia · Latvia - RecruitingPHASE3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
This study looks at a new way to treat a common eye condition called wet Age-related Macular Degeneration (AMD). It tests a small, refillable implant that delivers medicine directly to the eye, hoping to reduce how often people need eye injections.
For: Neovascular Age-related Macular DegenerationAustria · Czechia · Denmark - Active not recruitingPHASE3
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
This study looks at a new way to treat a common eye condition called 'wet' Age-related Macular Degeneration (nAMD). It tests how well a special eye implant works, which slowly releases medicine over a long time, compared to standard eye injections.
For: Neovascular Age-related Macular Degeneration (nAMD)Argentina · Australia · Austria